COVID-19 mRNA Vaccine: Early Findings in Older Adults

In a phase I trial, the SARS-CoV-2 mRNA-1273 vaccine was immunogenic and relatively safe in adults aged 56 and older.

Given the marked and progressive increase in COVID-19 disease severity with age in individuals older than 50 years, it is important that SARS-CoV-2 vaccines be safe and effective in this population. In a phase I dose-escalation trial supported by the National Institute of Allergy and Infectious Diseases and industry, investigators have now tested two doses of the SARS-CoV-2 mRNA-1273 candidate vaccine (25 µg or 100 µg) in 40 participants older than 55 years (20 age 56–70 years, 20 age >71 years; mean age, 69 years).

No serious adverse events were noted through 57 days. Among solicited symptoms, the most common were headache, myalagias, fatigue, chills, and injection-site pain. Symptoms occurred predominantly with the day-29 (second) dose and…

Reviewing Author

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

COVID-19 mRNA Vaccine: Early Findings in Older Adults

Topics

Reviewing Author